Instituto Butantan and SINOVAC will hold 'CoronaVac® Symposium' international event about efficacy and security of CoronaVac®
Instituto Butantan, in partnership with Sinovac Biotech, is pleased to announce CoronaVac® Symposium, an international online event that aims to promote and discuss the latest results of the efficacy and security of CoronaVac® and the scientific fundamentals of the effectiveness study Project S, that took place in the municipality of Serrana.
The scientific meeting will bring together Brazilian specialists from the United States, Turkey, Chile, China and Spain who will promote deep and qualified dialogues. Among the topics discussed are: the history of the vaccine that, till this moment, is the most applied in the world protecting people from Covid-19, CoronaVac®, and its immunogenicity among elderly and pediatric population; positive responses to the third dose or booster dose and the questions abouT immunization time in different countries.
This is a free online event, open to the general public.
Day 1----7th December 2021
The main subject in the first day is the CoronaVac® development as a historical mark of international immunization to combat the SAR-CoV-2 virus, from the first base researches to the last outcomes of effectiveness and security showed in S Project, Serrana, in São Paulo and in other countries. The opening session of the symposium will be held by the president of Butantan Institute, Dimas Covas and the president of Sinovac Biotech, Weidog Yin.
Day 2----8th December 2021
The CoronaVac underpinning Science about immunogenicity and security of the booster dose of vaccination with the inactivated SARS-CoV-2 will be presented on the second day of the international online symposium. The research outcomes will show the outreach, the potency and duration of CoronaVac immunization in several countries.
Day 3----9th December 2021
The symposium closing session will highlight the immunization outcomes among different groups of population, especially the clinic trials among patients with comorbidities, elderly, children and adolescents.
Information from https://coronavacsymposium.butantan.gov.br/
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion.
For more information, please visit the Company’s website at www.sinovac.com.
Sinovac Biotech Ltd.